D05.00
Lobular carcinoma in situ of unspecified breast
Clinical Classification Guidelines
Medical Intelligence & Overview
Lobular carcinoma in situ (LCIS) of the breast is a condition characterized by the abnormal growth of cells within the milk lobules of the breast. Despite being termed 'carcinoma,' LCIS is not cancer and is often considered a marker indicating an increased risk of developing breast cancer in the future. It is typically discovered incidentally during breast biopsies performed for other reasons. Understanding LCIS can help in making informed decisions about monitoring and management, ensuring women's health is optimized through appropriate care.
Causes & Symptoms
Clinical Causes: Genetic factors that predispose individuals to abnormal cell growth Hormonal influences, including prolonged exposure to estrogen Family history of breast cancer or other related cancers Lifestyle factors such as alcohol consumption and lack of physical activity Previous radiation therapy to the chest area
Key Symptoms: Often asymptomatic; no noticeable lumps or changes in the breast Detected incidentally during routine screening or biopsy In some cases, minor tenderness or thickening may be noted No visible skin changes or nipple discharge typically associated
Diagnostic & Treatment
Diagnosis Path: LCIS is usually diagnosed through tissue sampling obtained during a breast biopsy. Imaging techniques like mammography or ultrasound may not always detect LCIS directly, as it often doesn't form a distinct lump. Pathological examination under the microscope confirms the abnormal cell growth confined within the lobules. Additional tests such as genetic profiling or molecular studies may be recommended for comprehensive assessment. Regular follow-up imaging and physical exams are essential for women with diagnosed LCIS to monitor changes or progression.
Treatment Protocols: Management of LCIS depends on the individual case, overall health, and risk factors. Common approaches include: - Active surveillance with regular imaging and clinical exams - Risk-reducing medications like tamoxifen or raloxifene to lower the likelihood of developing invasive breast cancer - Sometimes surgical options, such as excision or removal of the affected area, are considered - Lifestyle modifications to reduce overall breast cancer risk, including maintaining a healthy weight and limiting alcohol intake Decisions regarding treatment should be made collaboratively between healthcare providers and patients, considering personal risk factors and preferences.
Clinical Advice & FAQs
Billing Guidance
Is D05.00 a billable ICD-10 code?
Yes, D05.00 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D05.00?
Clinical documentation must specify the nature of Lobular carcinoma in situ of unspecified breast and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
